Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline...
Results
REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 Anticipate reporting data from REVEAL-1...
BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative...
Financial Highlights: Reported Second Quarter Net Income of Nearly $5 Million Generated Nearly $13 Million of Operating Cash Flow During...
Agios Pharmaceuticals reported Q3 2024 financial results and business highlights. The company achieved $9.0 million...
Evaxion Biotech (NASDAQ: EVAX) announced Q3 2024 financial results and business updates. Key highlights include...
